Hemogenyx
HEMO.LHemogenyx Pharmaceuticals Plc Price (HEMO.L)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
1,129,136,727
(15.2475)%Income Statement Summary
| Revenue | |
| Cost of Revenue | |
| Gross Profit | |
| Operating Expenses | |
| Operating Income | |
| Other Expenses | |
| Net Income |
Income Statement
Hemogenyx Pharmaceuticals PlcCurrency: GBp
| YEAR | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Revenue |
0.00
+0% |
6,845.42
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
|||||||||
| Cost of Revenue | |||||||||||||||||||
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 100,481.00 | 348,266.00 | 421,817.00 | 350,719.00 | 283,647.00 | 2,599,762.00 | 645,681.00 | |||||||||
| Gross Profit | |||||||||||||||||||
| Gross Profit |
0.00
+0% |
6,845.42
+0% |
0.00
+0% |
-100,481.00
+0% |
-348,266.00
+247% |
-421,817.00
+21% |
-350,719.00
-17% |
-283,647.00
-19% |
-2,599,762.00
+817% |
-645,681.00
-75% |
|||||||||
| Gross Profit Ratio | (0.00%) | (1.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||
| Operating Expenses | |||||||||||||||||||
| Research and Development | 0.00 | 0.00 | 1,619.00 | 14,046.00 | 57,653.00 | 21.25 | 83.66 | 37.58 | 402.94 | 90,632.00 | |||||||||
| General and Administrative | 6,270.00 | 174,302.00 | 331,591.00 | 390,661.00 | 402,979.00 | 429,071.00 | 623,843.00 | 1,396,852.00 | 942,352.00 | 4,912,867.00 | |||||||||
| Selling, General & Admin... | 6,270.00 | 176,702.00 | 411,991.00 | 410,155.00 | 417,611.00 | 462,576.00 | 628,061.00 | 1,396,852.00 | 942,352.00 | 4,912,867.00 | |||||||||
| Selling & Marketing Exp... | 0.00 | 2,400.00 | 80,400.00 | 19,494.00 | 14,632.00 | 33,505.00 | 4,218.00 | 0.00 | 0.00 | 0.00 | |||||||||
| Depreciation and Amortiz... | 0.00 | 169,856.00 | 11,870.00 | 33,614.00 | 51,805.00 | 94,726.00 | 106,753.00 | 126,340.00 | 564,072.00 | 645,681.00 | |||||||||
| Other Expenses | 0.00 | 0.00 | 0.00 | 101,138.00 | 91,357.00 | 786,718.00 | 1,237,517.00 | 1,150,123.00 | 1,988,373.00 | 0.00 | |||||||||
| Total Operating Expenses | 6,270.00 | 176,702.00 | 411,991.00 | 690,688.00 | 1,261,714.00 | 1,249,294.00 | 1,865,578.00 | 2,546,975.00 | 2,930,725.00 | 4,912,867.00 | |||||||||
| Cost and Exponses | 6,270.00 | 176,702.00 | 411,991.00 | 791,169.00 | 1,609,980.00 | 1,671,111.00 | 2,216,297.00 | 2,830,622.00 | 5,530,487.00 | 5,558,548.00 | |||||||||
| Operating Income | |||||||||||||||||||
| Operating Income |
-6,270.00
+0% |
-169,856.59
+2,609% |
-519,898.00
+206% |
-820,976.00
+58% |
-1,615,235.00
+97% |
-1,684,133.00
+4% |
-2,150,386.00
+28% |
-2,702,754.00
+26% |
3,997,548.00
-248% |
-5,558,548.00
-239% |
|||||||||
| Operating Income Ratio | (0.00%) | (-24.81%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||
| Other Income and Exp... | |||||||||||||||||||
| Interest Income | 0.00 | 11,019.00 | 0.00 | 0.00 | 4,374.00 | 14,191.00 | 3,365.00 | 17,958.00 | 10,599.00 | 85,344.00 | |||||||||
| Interest Expenses | 0.00 | 0.00 | 0.00 | 10,741.00 | 1,779.00 | 31,328.00 | 33,239.00 | 2,595,389.00 | 33.00 | 315,991.00 | |||||||||
| Total Other Income/Exp... | 0.00 | -11,019.13 | -60,876.00 | -1,540,623.00 | 27,160.00 | 195,989.00 | 55,363.00 | -2,405,556.00 | 10,566.00 | -1,137,945.00 | |||||||||
| EBITDA | |||||||||||||||||||
| EBITDA | -6,270.00 | -0.59 | -447,152.00 | -837,060.00 | -1,630,222.00 | -1,362,095.00 | -1,955,028.00 | -2,386,584.00 | -3,422,876.00 | -5,734,823.00 | |||||||||
| EBITDA ratio | (0.00%) | (-1.61%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||
| Income Before Tax | |||||||||||||||||||
| Income Before Tax | -6,270.00 | -180,875.72 | -519,898.00 | -2,361,599.00 | -1,521,283.00 | -1,488,144.00 | -2,095,023.00 | -5,108,310.00 | -3,986,982.00 | -6,696,493.00 | |||||||||
| Income Before Tax Ratio | (0.00%) | (-26.42%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||
| Income Tax Expense | |||||||||||||||||||
| Income Tax Expense | 0.00 | -11,018.54 | 183,744.00 | -49,698.00 | -43,751.00 | -35,000.00 | 20,436.00 | 2,414,432.00 | 361,158.00 | 0.00 | |||||||||
| Net Income | |||||||||||||||||||
| Net Income | -6,270.00
+0% |
-180,875.72
+2,785% |
-519,898.00
+187% |
-2,361,599.00
+354% |
-1,477,532.00
-37% |
-1,453,144.00
-2% |
-2,115,459.00
+46% |
-7,522,742.00
+256% |
-4,348,140.00
-42% |
-6,690,678.00
+54% |
|||||||||
| Net Income Ratio | (0.00%) | (-26.42%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||
| Earning Per Share | |||||||||||||||||||
| Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 | |||||||||
| Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | -0.01 | |||||||||
| Share Outstanding | |||||||||||||||||||
| Basic Share Outstanding | 64,900,000.00 | 12,657,000.00 | 65,173,973.00 | 260,270,698.00 | 360,125,230.00 | 360,719,748.00 | 414,833,093.00 | 773,952,166.00 | 979,749,321.00 | 1,129,228,000.00 | |||||||||
| Diluted Share Outstanding | 64,900,000.00 | 12,657,692.00 | 65,173,973.00 | 260,270,699.00 | 360,125,230.00 | 360,719,748.00 | 414,833,093.00 | 773,952,166.00 | 979,749,321.00 | 1,129,136,727.00 | |||||||||